Prescient Therapeutics gets FDA orphan drug status for PTX-100 in PTCL
Prescient Therapeutics has secured the orphan drug designation for its PTX-100 compound from the US Food and Drug Administration (FDA) for the treatment of peripheral T-cell lymphomas (PTCL). According to the Australian oncology company, the FDA orphan drug designation will enable it in getting incentives that can help the development of PTX-100, which is a […]